Genentech started working on PI3K nearly two decades ago ... “If we can add a PI3K-mutation drug to first-line therapy,” ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Argonne National Laboratory, Flagship Pioneering, Terray, Weights & Biases and Dozens More Organizations Among Contributors ...

Recursion, a tech-driven biopharmaceutical company, is making strides in its drug discovery pipeline with ... jumped due to partnerships with Roche-Genentech, emphasizing its robust tech-enabled ...

The company has submitted an Investigational New Drug application for a promising treatment targeting ... The collaboration with Genentech to develop genomic medicines for neurodegenerative diseases ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

SALMONELLA is normally associated with violent food poisoning. But now scientists believe the horror bug could be manipulated ...

walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data. UCB granted Roche and its biotech unit Genentech an exclusive ...

3:47 PM ESTTechnology FDA approves Genentech drug aimed at subset of breast cancer patients FDA approves Genentech drug aimed at subset of breast cancer patients ...